Literature DB >> 15383793

Utilizing alpha-fetoprotein expression to enhance oncolytic viral therapy in hepatocellular carcinoma.

Richard H Pin1, Maura Reinblatt, Yuman Fong.   

Abstract

OBJECTIVE: To determine whether alpha-fetoprotein (AFP)-regulated ribonucleotide reductase (RR) production would promote more vigorous and specific viral killing in AFP-expressing hepatocellular carcinoma (HCC).
BACKGROUND: AFP is expressed in over 70% of primary HCC but not in normal adult liver. AFP production by HCC can be exploited to target viral killing of tumor cells. G207 is an oncolytic herpes virus lacking UL39, the gene encoding RR. RR is an enzyme required for viral DNA synthesis and cytotoxicity.
METHODS: Enzyme-linked immunosorbent assay (ELISA) was performed for AFP levels on Hep3B and PLC5 human HCC cells. An AFP-albumin enhancer-promoter complex (AFP-alb) was constructed in a luciferase vector to assess function. AFP-alb was cloned upstream of UL39 (AFP-alb/UL39) and transfected into HCC cells for G207 cytotoxicity assays. Viral plaque forming assays evaluated G207 replication. Hep3B flank tumors, with and without AFP-alb/UL39 transfection, were established in athymic mice (n = 28) and treated with G207.
RESULTS: Hep3B had 5-fold higher AFP levels than PLC5 (P < 0.00001). AFP-alb increased luciferase expression 72-fold in Hep3B (P < 0.001) and 3-fold in PLC5 (P < 0.001). AFP-alb/UL39 transfection increased G207 cytotoxicity 93% in Hep3B (P < 0.0005), with no significant increase in PLC5. Peak viral titers were 46-fold higher in Hep3B transfected with AFP-alb/UL39 versus mock-transfected cells (P < 0.01), with no significant change in PLC5. Flanks tumors transfected with AFP-alb/UL39 and treated with G207 demonstrated a 76% volume reduction versus mock-transfected tumors infected with G207 (P < 0.0001).
CONCLUSIONS: AFP-driven RR production by hepatoma cells significantly enhances herpes viral cytotoxicity and specificity in vitro and reduces tumor burden in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15383793      PMCID: PMC1356467          DOI: 10.1097/01.sla.0000141197.57930.7a

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  17 in total

1.  Evolution of the albumin: alpha-fetoprotein ancestral gene from the amplification of a 27 nucleotide sequence.

Authors:  F Alexander; P R Young; S M Tilghman
Journal:  J Mol Biol       Date:  1984-02-25       Impact factor: 5.469

2.  The targeted expression of the human interleukin-2/interferon alpha2b fused gene in alpha-fetoprotein-expressing hepatocellular carcinoma cells.

Authors:  P He; Z Y Tang; B B Liu; S L Ye; Y K Liu
Journal:  J Cancer Res Clin Oncol       Date:  1999       Impact factor: 4.553

3.  A position-dependent silencer plays a major role in repressing alpha-fetoprotein expression in human hepatoma.

Authors:  H Nakabayashi; T Hashimoto; Y Miyao; K K Tjong; J Chan; T Tamaoki
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

4.  A novel approach for inducing enhanced and selective transgene expression in hepatocellular-carcinoma cells.

Authors:  G Cao; S Kuriyama; H Tsujinoue; Q Chen; A Mitoro; Z Qi
Journal:  Int J Cancer       Date:  2000-07-15       Impact factor: 7.396

5.  Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant.

Authors:  T Mineta; S D Rabkin; R L Martuza
Journal:  Cancer Res       Date:  1994-08-01       Impact factor: 12.701

6.  Tandem arrangement of the albumin and alpha-fetoprotein genes in the human genome.

Authors:  Y Urano; M Sakai; K Watanabe; T Tamaoki
Journal:  Gene       Date:  1984-12       Impact factor: 3.688

7.  The gene map of the Norway rat (Rattus norvegicus) and comparative mapping with mouse and man.

Authors:  G Levan; J Szpirer; C Szpirer; K Klinga; C Hanson; M Q Islam
Journal:  Genomics       Date:  1991-07       Impact factor: 5.736

8.  raf regulates the postnatal repression of the mouse alpha-fetoprotein gene at the posttranscriptional level.

Authors:  J Vacher; S A Camper; R Krumlauf; R S Compton; S M Tilghman
Journal:  Mol Cell Biol       Date:  1992-02       Impact factor: 4.272

9.  Genetic analysis of alpha-fetoprotein synthesis in mice.

Authors:  A Belayew; S M Tilghman
Journal:  Mol Cell Biol       Date:  1982-11       Impact factor: 4.272

10.  Cell-specific enhancer activity in a far upstream region of the human alpha-fetoprotein gene.

Authors:  K Watanabe; A Saito; T Tamaoki
Journal:  J Biol Chem       Date:  1987-04-05       Impact factor: 5.157

View more
  6 in total

1.  ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.

Authors:  J Carson; D Haddad; M Bressman; Y Fong
Journal:  Drugs Future       Date:  2010       Impact factor: 0.148

2.  Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.

Authors:  Jing-Ping Liou; Shiow-Lin Pan; Che-Ming Teng; Chun-Han Chen; Mei-Chuan Chen; Jing-Chi Wang; An-Chi Tsai; Ching-Shih Chen
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

3.  Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo.

Authors:  Anna-Maria Anesti; Guy R Simpson; Toby Price; Hardev S Pandha; Robert S Coffin
Journal:  BMC Cancer       Date:  2010-09-13       Impact factor: 4.430

Review 4.  Oncolytic Adenoviruses in Gastrointestinal Cancers.

Authors:  Raquel T Yokoda; Bolni M Nagalo; Mitesh J Borad
Journal:  Biomedicines       Date:  2018-03-11

5.  Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy.

Authors:  Thomas R Whisenhunt; Kiran F Rajneesh; James R Hackney; James M Markert
Journal:  Oncolytic Virother       Date:  2015-01-30

Review 6.  Oncolytic virotherapy in upper gastrointestinal tract cancers.

Authors:  Raquel Yokoda; Bolni M Nagalo; Mansi Arora; Jan B Egan; James M Bogenberger; Thomas T DeLeon; Yumei Zhou; Daniel H Ahn; Mitesh J Borad
Journal:  Oncolytic Virother       Date:  2018-03-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.